ProfoundBio

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies

Shots: Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s ADC technologies for one therapeutic program to targets specific TAA & also retains license option rights to a second TAA The agreement will access Synaffix’s linker-payload technologies including GlycoConnect & …

Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies Read More »